Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | FTH1 | P02794 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979491 | 1.00 | FNTA (0.33) | FNTAFNTBPGGT1BPTGS2KDR | |
| SCHEMBL13216859 | 0.90 | FNTA (0.32) | FNTAFNTBPGGT1BPTGS2 | |
| SCHEMBL14486589 | 0.82 | CYP3A4 (0.35) | CYP3A4FTH1CYP2C9CYP2C19 | |
| SCHEMBL9979496 | 0.78 | HSD11B1 (0.33) | HSD11B1CYP3A4HSD11B2 | |
| SCHEMBL9979494 | 0.78 | HSD11B1 (0.35) | KDRHSD11B1CYP3A4HSD11B2 | |
| SCHEMBL9979495 | 0.75 | CYP3A4 (0.36) | CYP3A4FTH1CYP2C9CYP2C19 | |
| SCHEMBL31424073 | 0.69 | FNTA (0.58) | FNTAFNTBPGGT1BPTGS2CYP3A4 | |
| SCHEMBL31424068 | 0.69 | FNTA (0.58) | FNTAFNTBPGGT1BPTGS2CYP3A4 | |
| SCHEMBL16943993 | 0.64 | ALDH1A1 (0.39) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13355527 | 0.63 | CYP3A4 (0.39) | CYP3A4FTH1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20240269192-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | SPINALCYTE LLC (US) | 2024-08-15 | — | — | US | claimed |
| EP-4355342-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | Spinalcyte, LLC (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20240024363-A1 | TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-01-25 | — | — | US | claimed |
| US-20230364143-A1 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2023-11-16 | — | — | US | claimed |
| US-20230330193-A1 | ENHANCEMENT OF STEM CELL THERAPY FOR CARTILAGE DEGENERATION BY ANTI-OXIDANT PRE-CONDITIONING | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2023-10-19 | — | — | US | claimed |
| US-20230165918-A1 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | FIGENE, LLC | 2023-06-01 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2022266485-A1 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | SPINALCYTE LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220395540-A1 | TREATMENT OF COVID-19 LUNG INJURY USING UMBILICAL CORD PLASMA BASED COMPOSITIONS | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-12-15 | — | — | US | claimed |
| US-20220362341-A1 | TREATMENT OF MAJOR DEPRESSIVE DISORDER BY LOW DOSE INTERLEUKIN-2 | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-11-17 | — | — | US | claimed |
| US-20220175701-A1 | TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-06-09 | — | — | US | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20220088086-A1 | Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | FNTA 1266/4885FNTB 2565/4885PGGT1B 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.